Anthrax

1. Clinical Overview

Summary

Anthrax is a potentially fatal infection caused by the spore-forming, Gram-positive bacterium Bacillus anthracis. Primarily a disease of herbivorous animals (cattle, sheep, goats), it is transmitted to humans through contact with infected animals or contaminated animal products. The disease manifests in four distinct clinical forms based on route of exposure: cutaneous anthrax (95% of natural cases), characterised by the pathognomonic painless black eschar; inhalational anthrax ("woolsorter's disease"), presenting with the classic widened mediastinum on chest radiography and carrying mortality rates of 45-92% despite treatment; gastrointestinal anthrax, acquired through consumption of contaminated meat; and injectional anthrax, a recently described form associated with contaminated heroin use. [1,2]

Bacillus anthracis is classified as a Category A bioterrorism agent by the CDC due to its stability as spores (surviving decades in soil), ease of dissemination, high mortality potential, and capacity to cause public panic. The 2001 United States postal attacks demonstrated this threat, resulting in 22 cases (11 inhalational, 11 cutaneous) and 5 deaths. [3,4]

The pathogenicity of B. anthracis stems from its two principal virulence factors: a poly-D-glutamic acid capsule (unique among bacteria) that confers resistance to phagocytosis, and a tripartite exotoxin system consisting of protective antigen (PA), lethal factor (LF), and oedema factor (EF). These components combine to form lethal toxin (LeTx = PA + LF) and oedema toxin (EdTx = PA + EF), which mediate the characteristic tissue necrosis, massive oedema, and systemic toxicity. [5,6]

Treatment requires prompt initiation of combination antimicrobial therapy (ciprofloxacin or doxycycline plus a second agent such as meropenem, linezolid, or clindamycin for systemic disease) and antitoxin administration (raxibacumab or anthrax immune globulin) in severe cases. Post-exposure prophylaxis (PEP) with 60 days of antimicrobials ± vaccination is critical following suspected spore exposure. Notifiable disease status mandates immediate reporting to public health authorities. Despite modern intensive care, inhalational anthrax carries mortality rates of 45-61% with treatment (approaching 85-90% if untreated). [7,8]

Clinical Pearls

"Malignant Pustule" is a Misnomer: Despite this historical term, the cutaneous lesion is neither malignant nor pustular. It is a painless, dry, black eschar surrounded by gelatinous, non-pitting oedema. Pain suggests secondary bacterial infection.

Widened Mediastinum = Haemorrhagic Lymphadenitis: The pathognomonic chest radiograph finding in inhalational anthrax results from haemorrhagic necrosis of mediastinal lymph nodes, not pneumonia. Parenchymal infiltrates are typically absent in early disease.

"Black as Coal": The term "anthrax" derives from the Greek ἄνθραξ (coal), referring to the characteristic black eschar. This clinical sign is virtually pathognomonic in the appropriate epidemiological context.

Binary Toxin Mechanism: Unlike single-component toxins, anthrax toxins require protective antigen (PA) to bind cell receptors and transport enzymatic components (LF or EF) into cells. This AB toxin structure is the target of antitoxin therapy.

60-Day Treatment Duration: The extended antimicrobial course accounts for the prolonged germination period of spores, which can remain dormant in mediastinal lymph nodes for up to 60 days before causing disease.

Human-to-Human Transmission Does Not Occur: Anthrax is not contagious between humans. Standard infection control precautions are sufficient; airborne or enhanced barrier precautions are unnecessary.

---

2. Epidemiology

Global Distribution

The global incidence is estimated at 2,000-20,000 cases annually, predominantly cutaneous anthrax in agricultural regions. Actual incidence is likely underreported due to surveillance limitations in endemic areas. [9,10]

Demographics and Risk Factors

Historical Outbreaks and Events

Transmission Routes

Exam Detail: Spore Biology and Environmental Persistence:

Bacillus anthracis forms metabolically dormant endospores when environmental conditions become unfavorable. These spores possess extraordinary resistance:

• Heat resistance: Survive 100°C for 10 minutes; require autoclaving (121°C, 15 minutes) for reliable destruction
• Chemical resistance: Resist alcohol, quaternary ammonium compounds; require sporicidal agents (10% hypochlorite, peracetic acid, formaldehyde)
• Environmental persistence: Remain viable in soil for decades to centuries; documented cases of reactivation after > 100 years
• Low infectious dose: Estimated 8,000-50,000 spores for inhalational anthrax (varies by route and strain)

The multilayered spore structure comprises:

1. Core: Contains DNA, ribosomes, essential enzymes; extreme dehydration
2. Inner membrane: Surrounds core; modified lipid composition
3. Cortex: Peptidoglycan layer; maintains core dehydration
4. Coat: Proteinaceous layers providing chemical and enzymatic resistance
5. Exosporium: Glycoprotein and lipid outer layer

This structure explains why environmental decontamination following bioterrorism events (e.g., 2001 postal attacks) required aggressive sporicidal treatments and prolonged facility closures.

---

3. Aetiology and Pathophysiology

Microbiology

Organism: Bacillus anthracis

Virulence Factors

1. Capsule (encoded by pXO2 plasmid)

• Composition: Poly-D-glutamic acid (unique polypeptide capsule)
• Function: Antiphagocytic; inhibits complement deposition
• Detection: India ink stain or immunofluorescence
• Clinical significance: Essential for virulence; capsule-negative strains are avirulent

2. Tripartite Exotoxin System (encoded by pXO1 plasmid)

The anthrax toxin system consists of three independently non-toxic proteins that combine to form two binary toxins:

Binary Toxin Formation:

1. Lethal Toxin (LeTx) = PA + LF

   • LF cleaves mitogen-activated protein kinase kinases (MAPKKs)
   • Disrupts cellular signaling cascades
   • Causes macrophage cytolysis and apoptosis
   • Induces cytokine storm (TNF-α, IL-1β)
   • Results in vascular collapse and shock

2. Oedema Toxin (EdTx) = PA + EF

   • EF increases intracellular cAMP (1000-fold elevation)
   • Disrupts water homeostasis
   • Causes massive interstitial oedema
   • Impairs neutrophil function and phagocytosis
   • Contributes to the characteristic gelatinous oedema of cutaneous anthrax

Exam Detail: Molecular Mechanism of Toxin Action (Classic Viva Topic):

Step 1: PA Binding

• PA83 binds to cell surface receptors (ANTXR1/TEM8 or ANTXR2/CMG2)
• Host cell furin protease cleaves PA83 → PA63 + PA20
• PA20 dissociates; PA63 oligomerizes into heptameric or octameric pore

Step 2: LF/EF Binding and Internalization

• Up to 3 molecules of LF and/or EF bind to PA63 oligomer
• Receptor-mediated endocytosis of toxin complex
• Acidification of endosome triggers PA63 pore formation in endosomal membrane

Step 3: Translocation

• PA63 pore translocates LF and/or EF into cytoplasm
• Unfolding of LF/EF required for passage through narrow PA63 channel

Step 4: Enzymatic Activity

• LF: Cleaves MAPKKs (MEK1, MEK2, MEK3, MEK4, MEK5, MEK6, MEK7)

  • Disrupts MAPK signaling pathways (ERK, p38, JNK)
  • Induces macrophage pyroptosis via NLRP1 inflammasome activation
  • Causes endothelial dysfunction and vascular leak
  • Impairs dendritic cell maturation and adaptive immunity

• EF: Adenylate cyclase activity (requires calmodulin)

  • Converts ATP → cAMP (supraphysiological levels)
  • Activates protein kinase A (PKA)
  • Impairs neutrophil chemotaxis, phagocytosis, and oxidative burst
  • Increases vascular permeability
  • Disrupts tight junctions

Clinical Correlation:

• LeTx dominance in systemic disease → shock, multi-organ failure
• EdTx dominance in cutaneous disease → massive local oedema
• Both toxins synergize to impair host defenses and promote bacterial dissemination

Therapeutic Target:

• Raxibacumab and obiltoxaximab are monoclonal antibodies that bind PA, preventing toxin assembly and receptor binding
• Anthrax immune globulin provides polyclonal anti-PA and anti-LF/EF antibodies
• These agents neutralize circulating toxin but do not affect intracellular toxin already translocated

Pathogenesis

The pathogenesis varies by route of exposure but follows a common sequence after spore entry:

Phase 1: Spore Entry and Germination

Germination triggers:

• High CO₂ concentration
• Presence of L-alanine and inosine (released by mammalian cells)
• Neutral pH
• Warm temperature (37°C)

Spores transition from dormant endospore → metabolically active vegetative bacilli within 1-4 hours after phagocytosis.

Phase 2: Local Replication and Toxin Production

• Vegetative bacilli express capsule (from pXO2) and toxin genes (from pXO1)
• Capsule prevents phagocytosis and complement-mediated killing
• Local toxin production causes:
  • "Cutaneous: Gelatinous oedema (EdTx) and central necrosis (LeTx) → eschar formation"
  • "Inhalational: Haemorrhagic mediastinitis and lymphadenitis"
  • "Gastrointestinal: Mucosal ulceration, bowel wall oedema, mesenteric adenitis"

Phase 3: Lymphatic Dissemination

• Encapsulated bacilli resist killing and drain to regional lymph nodes
• Massive bacterial replication in lymphoid tissue
• Haemorrhagic necrosis of lymph nodes (pathognomonic histology)
• Inhalational anthrax: Haemorrhagic mediastinal lymphadenopathy → widened mediastinum on CXR

Phase 4: Bacteraemia and Systemic Toxemia

• Lymphatic barrier failure → high-grade bacteraemia (10⁴-10⁸ CFU/mL)
• Circulating toxins cause:
  • "Vascular leak: Massive third-spacing, pleural and pericardial effusions"
  • "Cytokine storm: TNF-α, IL-1β, IL-6 → systemic inflammatory response syndrome (SIRS)"
  • "Myocardial dysfunction: Direct LeTx effect on cardiomyocytes"
  • "Coagulopathy: Consumptive coagulopathy and DIC"
  • "Shock: Distributive shock (vasodilatory) + cardiogenic component"
  • "Meningitis: Haemorrhagic meningitis in 50% of inhalational cases (CSF appears grossly bloody)"

Phase 5: Multi-Organ Failure and Death

• Cardiovascular collapse
• Respiratory failure (pulmonary oedema, ARDS)
• Acute kidney injury
• Hepatic dysfunction
• Death typically within 24-36 hours of fulminant phase onset without treatment

Exam Detail: Why Does Inhalational Anthrax Have Such High Mortality?

Several factors contribute to the devastating lethality of inhalational anthrax:

1. Silent Incubation: Spores remain dormant in mediastinal lymph nodes for days; germination is asynchronous and can occur up to 60 days post-exposure (explaining need for 60-day PEP).

2. Delayed Recognition: Non-specific prodrome ("flu-like illness") → patients present after extensive toxin accumulation and high bacterial burden.

3. Overwhelming Toxemia: By the time of fulminant presentation, massive quantities of LeTx and EdTx are already circulating and intracellular. Antibiotics kill bacteria but do not neutralize existing toxin.

4. Mediastinal Catastrophe: Haemorrhagic mediastinitis causes:

   • Mechanical compression of great vessels and airways
   • Massive haemorrhagic pleural effusions (often requiring drainage)
   • Pericardial involvement and cardiac tamponade

5. Haemorrhagic Meningitis: Occurs in ~50% of inhalational cases; almost universally fatal even with treatment; CSF shows RBCs, bacteria, extremely elevated protein.

6. Immunological Impairment: Toxins disable immune cells (macrophages, neutrophils, dendritic cells), preventing effective clearance even with antimicrobials.

7. Rapid Progression: Fulminant phase evolves over hours; narrow window for effective intervention once systemic symptoms begin.

Historical Mortality Data:

• Pre-2001: Nearly 100% fatal (limited case experience)
• 2001 Outbreak with modern ICU care: 45% mortality (5/11 deaths)
• Sverdlovsk 1979: 86% mortality (58/68 with medical care; limited access to ICU)
• Untreated: > 85-90% mortality

Survival factors identified from 2001 outbreak:

• Early initiation of antimicrobials (before fulminant phase)
• Aggressive pleural fluid drainage
• Antitoxin administration (raxibacumab, anthrax immune globulin)
• Multi-agent antimicrobial therapy
• ICU-level supportive care

---

4. Clinical Presentation

Cutaneous Anthrax (95% of Natural Cases)

Cutaneous anthrax follows a characteristic temporal evolution:

Key Clinical Features:

• PAINLESS: Cardinal feature unless secondary bacterial infection occurs
• Black eschar: "Anthrax" from Greek ἄνθραξ (coal); virtually pathognomonic
• Massive oedema: Out of proportion to size of eschar; gelatinous, non-pitting
• No lymphangitis: Unlike streptococcal cellulitis (helps differentiate)
• Regional lymphadenopathy: Tender, enlarged regional nodes

High-Risk Anatomical Sites:

• Head and neck (40%): Risk of airway compromise, extensive facial oedema
• Upper extremities (35%): Farmer/worker contact with animal products
• Lower extremities (15%)
• Trunk (10%)

Systemic Features (10-20% of cutaneous cases if untreated):

• Fever (38-39°C)
• Malaise, headache
• Regional lymphadenopathy
• Bacteraemia (rare with treatment; common without)

Mortality:

• Treated: less than 1%
• Untreated: 5-20% (progression to systemic disease)

Exam Detail: Why is Cutaneous Anthrax Painless?

The painlessness of cutaneous anthrax, despite extensive tissue necrosis, results from several mechanisms:

1. Oedema toxin (EdTx) anesthetic effect: Massive local cAMP elevation disrupts nociceptor signaling and may directly impair pain fiber function.

2. Early microvasculature thrombosis: Lethal toxin causes endothelial damage and microvascular occlusion, leading to ischemic nerve injury before significant inflammation occurs.

3. Dry necrosis: The eschar is a dry coagulative necrosis (not suppurative), limiting inflammatory mediators that typically cause pain.

4. Impaired immune cell infiltration: Toxins disable neutrophils and macrophages, preventing the inflammatory infiltrate that produces pain mediators (prostaglandins, bradykinin).

Clinical Pearl: If a "cutaneous anthrax" lesion is painful, consider:

• Secondary bacterial infection (Staphylococcus, Streptococcus)
• Alternative diagnosis (spider bite, ecthyma gangrenosum, necrotizing fasciitis)
• Injectional anthrax (often painful due to deep tissue necrosis and compartment syndrome)

Inhalational Anthrax ("Woolsorter's Disease")

Inhalational anthrax is a biphasic illness with a deceptive prodrome followed by fulminant deterioration:

Prodromal Phase (Days 1-5)

"Flu-like illness" - non-specific symptoms leading to delayed diagnosis:

Prodrome duration: 1-5 days (mean 3 days)

Critical distinction from influenza:

• No rhinorrhea or sore throat (upper respiratory tract not involved)
• Retrosternal chest discomfort (suggests mediastinitis)
• Epidemiological context (occupational exposure, bioterrorism event)

Fulminant Phase (Days 3-7)

Sudden, catastrophic deterioration over hours:

Rapid progression: 50% of patients die within 24-48 hours of fulminant phase onset despite ICU care

Imaging Findings

Chest Radiograph (Pathognomonic):

• Widened mediastinum: > 8 cm at level of T4 (haemorrhagic mediastinal lymphadenopathy)
• Hilar fullness: Enlarged hilar lymph nodes
• Pleural effusions: Often bilateral; haemorrhagic on thoracentesis
• Absence of parenchymal infiltrates: Key differentiator from pneumonia (early disease)
• Pulmonary oedema: Late finding (ARDS from shock)

CT Chest (more sensitive):

• Haemorrhagic mediastinal lymphadenopathy (hyperdense nodes)
• Mediastinal oedema
• Haemorrhagic pleural effusions
• Ground-glass opacities (late, from oedema/ARDS)

Pleural Fluid Analysis:

• Grossly haemorrhagic (burgundy to dark red)
• Exudative
• Gram stain: may show bacilli
• Culture: often positive

Haemorrhagic Meningitis

Complicates ~50% of inhalational anthrax cases:

• Presentation: Severe headache, neck stiffness, altered mental status, seizures
• CSF appearance: Grossly bloody (resembles traumatic tap but does not clear)
• CSF analysis:
  • "RBCs: Hundreds to thousands per μL"
  • "WBCs: Elevated (1,000-10,000/μL); neutrophil-predominant"
  • "Protein: Markedly elevated (> 1,000 mg/dL)"
  • "Glucose: Markedly reduced (less than 20 mg/dL)"
  • "Gram stain: Gram-positive bacilli in chains"
• Prognosis: > 90% mortality despite treatment

Mortality (Inhalational Anthrax):

• Treated (modern era, 2001 outbreak): 45-61%
• Treated (historical, Sverdlovsk 1979): 86%
• Untreated: 85-90%

Exam Detail: The Sverdlovsk Outbreak (1979): A Biological Chernobyl

On April 2, 1979, an accidental release of aerosolized anthrax spores from a Soviet military microbiology facility (Compound 19) in Sverdlovsk (now Yekaterinburg), Russia, resulted in the largest documented outbreak of inhalational anthrax.

Epidemiological Features:

• Cases: 96-105 confirmed (estimates vary due to Soviet cover-up)
• Deaths: 64-68 (mortality ~67-68%)
• Incubation period: Ranged from 2-43 days (asynchronous spore germination)
• Plume extent: Cases occurred up to 4 km downwind from facility

Cover-Up and Discovery:

• Soviet government initially claimed outbreak was due to contaminated meat (gastrointestinal anthrax)
• Whistleblower allegations emerged in 1980s
• Confirmed as inhalational anthrax by Meselson investigation (1992-1994) after Soviet collapse
• Autopsy tissues showed haemorrhagic mediastinal lymphadenitis, not intestinal pathology

Scientific Insights:

• Demonstrated lethality of aerosolized spores
• Revealed prolonged incubation potential (up to 43 days)
• Informed biodefense preparedness and PEP duration (60 days)
• Highlighted diagnostic challenge (initial flu-like prodrome)

Bioterrorism Implications:

• Proved feasibility of anthrax as bioweapon
• Influenced Biological Weapons Convention enforcement
• Shaped modern biodefense stockpiling (antimicrobials, vaccines, antitoxins)

Gastrointestinal Anthrax

Two anatomical forms depending on site of spore deposition:

Oropharyngeal Form

Differential diagnosis: Diphtheria, Ludwig's angina, peritonsillar abscess

Intestinal Form

Imaging findings:

• Bowel wall thickening (ileum, cecum most commonly affected)
• Ascites (often haemorrhagic)
• Mesenteric lymphadenopathy (may be haemorrhagic)
• Free air (if perforation occurs)

Mortality:

• Treated: 25-60% (depends on early recognition)
• Untreated: > 50%

Pathophysiology: Spores deposited in oropharynx or ingested → germinate in mucosa → local ulceration and oedema → lymphatic spread → bacteraemia

Injectional Anthrax

Newly described clinical form identified during UK outbreak (2009-2012) among heroin users:

Epidemiology:

• 126 confirmed cases in UK, Germany, France, Denmark (2009-2012)
• 14 deaths (mortality ~11%)
• Source: Heroin contaminated with B. anthracis spores from Afghanistan

Clinical Presentation:

Distinguishing features from cutaneous anthrax:

• Pain is prominent (vs. painless cutaneous)
• Deeper tissue involvement (subcutaneous, muscle, fascia)
• Often requires surgical debridement or fasciotomy
• Higher risk of compartment syndrome

Management:

• Antimicrobials (as per systemic anthrax)
• Surgical debridement of necrotic tissue
• Fasciotomy if compartment syndrome
• ICU-level supportive care

---

5. Differential Diagnosis

Cutaneous Anthrax Mimics

Inhalational Anthrax Mimics

Gastrointestinal Anthrax Mimics

---

6. Investigations

Microbiological Diagnosis

Critical Safety Note: B. anthracis is a highly dangerous organism in the laboratory. Notify laboratory of suspected anthrax BEFORE sending specimens. Use biosafety level 2 (BSL-2) with BSL-3 practices for clinical specimens; BSL-3 for culture work.

Exam Detail: Laboratory Identification of Bacillus anthracis:

B. anthracis must be distinguished from non-pathogenic Bacillus species (e.g., B. cereus, B. subtilis, which are common environmental contaminants):

Key Differentiating Tests:

Reporting: Confirmed or suspected B. anthracis requires immediate notification to:

• Infection control
• Hospital epidemiology
• Public health authority (PHE/CDC)
• Law enforcement (if bioterrorism suspected)

Imaging

Chest Radiograph

Inhalational Anthrax:

• Widened mediastinum (> 8 cm at T4 level): Pathognomonic finding
• Hilar fullness/lymphadenopathy
• Pleural effusions (often bilateral)
• Absence of parenchymal consolidation (early disease)
• Pulmonary oedema (late, from ARDS)

CT Chest (High Resolution)

Findings in Inhalational Anthrax:

• Haemorrhagic mediastinal lymphadenopathy: Hyperdense lymph nodes (30-60 HU)
• Mediastinal fat stranding/oedema
• Haemorrhagic pleural effusions (hyperdense fluid)
• Ground-glass opacities (late)
• No lobar consolidation (differentiates from pneumonia)

CT Abdomen (GI Anthrax):

• Bowel wall thickening (ileum, cecum)
• Mesenteric lymphadenopathy
• Haemorrhagic ascites
• Portal venous gas (if bowel ischemia)

Routine Laboratory Tests

Cerebrospinal Fluid (if Meningitis Suspected)

Note: Lumbar puncture carries risk in setting of coagulopathy (DIC) and raised ICP. Perform only if meningitis alters management.

---

7. Management

Emergency Management Algorithm

SUSPECTED ANTHRAX
(Painless black eschar + oedema, OR widened mediastinum, OR bioterrorism event)
                       ↓
┌──────────────────────────────────────────────────────────────┐
│ IMMEDIATE ACTIONS (Within 1 Hour)                           │
├──────────────────────────────────────────────────────────────┤
│ 1. ISOLATE patient (Standard precautions; NOT airborne)     │
│ 2. NOTIFY:                                                   │
│    - Infectious diseases consultant                         │
│    - Public health authority (PHE/CDC) - NOTIFIABLE DISEASE │
│    - Hospital infection control                             │
│    - Law enforcement IF bioterrorism suspected              │
│ 3. OBTAIN specimens BEFORE antibiotics:                      │
│    - Blood cultures × 2-3 sets                              │
│    - Lesion swab/fluid (cutaneous)                          │
│    - Pleural fluid (if effusion)                            │
│    - CSF (if meningitis suspected + safe)                   │
│    - Notify lab of suspected anthrax (biosafety)            │
│ 4. IMAGING:                                                  │
│    - CXR (all cases - assess for mediastinal widening)      │
│    - CT chest (if inhalational anthrax suspected)           │
│ 5. START IV ACCESS, MONITORING, OXYGEN                      │
└──────────────────────────────────────────────────────────────┘
                       ↓
┌──────────────────────────────────────────────────────────────┐
│ CLINICAL CLASSIFICATION                                      │
└──────────────────────────────────────────────────────────────┘
                       ↓
    ┌──────────────────┬──────────────────┬─────────────────┐
    ↓                  ↓                  ↓                 ↓
CUTANEOUS        SYSTEMIC/INHALATIONAL  GI ANTHRAX   INJECTIONAL
(Uncomplicated)  (OR COMPLICATED         
                  CUTANEOUS)             
    ↓                  ↓                  ↓                 ↓
ORAL THERAPY     IV COMBINATION         IV COMBINATION   IV COMBINATION
                 THERAPY                THERAPY          + SURGERY

Antimicrobial Therapy

Cutaneous Anthrax (Uncomplicated, No Systemic Signs)

First-Line Oral Regimens:

Alternative Oral Agents (if fluoroquinolones/tetracyclines contraindicated):

• Amoxicillin 1 g PO TDS (if susceptibility confirmed; natural strains usually susceptible, weaponized strains may be resistant)
• Clindamycin 600 mg PO TDS

Special Populations:

• Pregnant women: Ciprofloxacin or levofloxacin (benefits outweigh theoretical risks)
• Children: Ciprofloxacin 10-15 mg/kg PO BD (max 500 mg/dose) OR Doxycycline if > 8 years

Duration Rationale: 60 days required because spores can remain dormant and germinate up to 60 days after initial exposure.

Exam Detail: Why 60-Day Antimicrobial Course?

This is a classic exam question testing understanding of anthrax pathophysiology:

Rationale:

1. Spores are metabolically dormant: Antibiotics only kill vegetative (actively replicating) bacteria, NOT spores.

2. Asynchronous germination: Spores germinate at variable times after initial exposure (documented range: 1-60 days; Sverdlovsk outbreak had cases up to 43 days post-exposure).

3. Lymph node reservoir: In inhalational exposure, spores persist in mediastinal lymph nodes and germinate over prolonged period.

4. Relapse risk: Premature discontinuation → spore germination after antibiotic cessation → clinical relapse.

Evidence Base:

• Sverdlovsk outbreak: Cases continued to emerge up to 43 days post-exposure
• Primate studies: 60-day antibiotic course required to prevent disease after aerosol exposure
• 2001 outbreak: CDC recommended 60 days based on primate data

Clinical Application:

• Post-exposure prophylaxis (PEP): 60 days ciprofloxacin/doxycycline
• Treatment of cutaneous anthrax: 60 days (even uncomplicated cases)
• Treatment of systemic anthrax: IV until clinically stable, then complete 60 days total PO

Systemic/Inhalational/GI/Complicated Anthrax

Require IV COMBINATION THERAPY (3-drug regimen):

Recommended Regimen (CDC Guidelines):

DRUG 1: Bactericidal (Fluoroquinolone OR Beta-Lactam)
   ├─ Ciprofloxacin 400 mg IV q8h (preferred)
   └─ OR Meropenem 2 g IV q8h

PLUS

DRUG 2: Protein Synthesis Inhibitor
   ├─ Linezolid 600 mg IV q12h (preferred - excellent CSF penetration)
   └─ OR Clindamycin 900 mg IV q8h (inhibits toxin production)

PLUS (if meningitis OR severe disease)

DRUG 3: Additional Agent
   └─ Meropenem 2 g IV q8h (if not already used as Drug 1)

Alternative Agents:

• Doxycycline 100 mg IV q12h (if fluoroquinolones contraindicated)
• Vancomycin 15 mg/kg IV q12h (if linezolid unavailable)
• Chloramphenicol 1 g IV q6h (good CSF penetration; historical use)
• Penicillin G 4 million units IV q4h (if confirmed susceptible; NOT for bioterrorism strains)

Duration:

• IV therapy: Until clinically stable (typically 2-3 weeks)
• Total duration: 60 days (transition to PO ciprofloxacin or doxycycline to complete)

Rationale for Combination Therapy:

1. Bactericidal activity: Rapid killing of vegetative bacteria
2. Toxin inhibition: Protein synthesis inhibitors (clindamycin, linezolid) reduce toxin production
3. CNS penetration: Linezolid, meropenem, chloramphenicol achieve therapeutic CSF levels
4. Synergy: Multi-drug regimen provides synergistic effect

Exam Detail: Why Combination Therapy for Systemic Anthrax?

Single-agent therapy is INADEQUATE for systemic anthrax. Here's why:

1. Overwhelming Bacterial Burden:

• Bacteraemia: 10⁴-10⁸ CFU/mL (extremely high)
• Monotherapy at this bacterial load risks inadequate killing rate

2. Toxin Production:

• Even dying bacteria release toxin (LeTx, EdTx)
• Protein synthesis inhibitors (clindamycin, linezolid) STOP further toxin production
• This is critical because existing circulating toxin is not affected by antibiotics

3. CNS Penetration:

• Meningitis occurs in ~50% of inhalational cases
• Ciprofloxacin has POOR CSF penetration (10-30% serum levels)
• Linezolid (> 80% CSF penetration) or meropenem (20-50%) or chloramphenicol (50-100%) required

4. Resistance Concerns:

• Engineered bioterrorism strains may have antibiotic resistance genes
• Combination therapy provides coverage if monoresistance present

5. Mortality Data:

• 2001 outbreak: Combination therapy → 45% mortality
• Historical monotherapy: > 80% mortality
• Primate models: Combination therapy superior to monotherapy

Classic Viva Question: Q: "What antibiotics would you use for inhalational anthrax with meningitis?" A: "Triple therapy with:

1. Ciprofloxacin 400 mg IV q8h (bactericidal, anti-PA activity)
2. Linezolid 600 mg IV q12h (excellent CSF penetration, inhibits protein synthesis)
3. Meropenem 2 g IV q8h (broad Gram-positive activity, good CSF penetration) Plus raxibacumab or anthrax immune globulin to neutralize circulating toxin."

Antitoxin Therapy

Indications: Systemic anthrax (inhalational, GI, injectional, complicated cutaneous, meningitis)

Rationale:

• Antibiotics kill bacteria but do NOT neutralize circulating toxin
• Antitoxin binds and neutralizes LeTx and EdTx already in circulation
• Most effective if given EARLY (before extensive toxin-mediated damage)

Evidence:

• Animal studies show significant mortality reduction
• 2001 outbreak: Antitoxin unavailable; modern recommendations based on subsequent research
• Now part of Strategic National Stockpile (SNS)

Administration:

• Give as EARLY as possible in systemic disease
• Administer AFTER antimicrobials started (avoid anaphylaxis from mass bacterial lysis)
• Premedicate with antihistamine (diphenhydramine) to reduce infusion reactions

Supportive Care

ICU-Level Care Required for Systemic Anthrax:

DO NOT:

• Incise or drain cutaneous lesions: Increases risk of bacteraemia and secondary infection
• Delay antibiotics for culture results: High mortality; start empirically if suspected

Post-Exposure Prophylaxis (PEP)

Indications:

• Known or suspected exposure to B. anthracis spores (bioterrorism event, laboratory accident)
• Close contact with confirmed inhalational anthrax case (rare; not person-to-person transmission)

Regimen:

Alternative antimicrobials (if fluoroquinolones/tetracyclines contraindicated):

• Amoxicillin 1 g PO TDS
• Levofloxacin 750 mg PO OD

Special Populations:

• Pregnant/breastfeeding: Ciprofloxacin or levofloxacin (risks of anthrax exceed theoretical antibiotic risks)
• Children: Ciprofloxacin 10-15 mg/kg PO BD (max 500 mg) OR Doxycycline 2.5 mg/kg PO BD (if > 8 years)

Monitoring:

• Daily symptom surveillance (fever, cough, dyspnea, chest pain)
• Immediate evaluation if symptoms develop

Vaccination

Anthrax Vaccine Adsorbed (AVA, BioThrax™):

Composition: Cell-free filtrate of B. anthracis culture (contains PA, other proteins)

Indications:

• Occupational exposure: Military personnel, laboratory workers handling B. anthracis, certain animal handlers
• Post-exposure prophylaxis (in combination with antimicrobials)

Schedule:

• Pre-exposure: 5 doses (0, 1, 6, 12, 18 months) + annual boosters
• Post-exposure (accelerated): 3 doses (0, 2, 4 weeks) + antimicrobials × 60 days

Efficacy: ~90% effective in preventing anthrax (based on animal and human data)

Adverse effects: Local reactions (pain, erythema), systemic (fever, myalgia); rare serious reactions

Availability: Limited supply; primarily military and public health stockpile (US Strategic National Stockpile)

Public Health Response

Notifiable Disease: IMMEDIATE NOTIFICATION REQUIRED

Infection Control:

• Standard precautions sufficient (gloves, gown if contact with lesions)
• NOT contagious person-to-person (no airborne or droplet precautions needed)
• Safe handling of lesion drainage: Autoclave or incinerate contaminated materials

---

8. Complications

---

9. Prognosis and Outcomes

Mortality by Clinical Form

Prognostic Factors

Favorable:

• Early initiation of antimicrobials (before fulminant phase)
• Cutaneous form (localized disease)
• Absence of systemic signs (fever, tachycardia, hypotension)
• Access to ICU-level care
• Antitoxin availability and early administration
• Younger age, no comorbidities

Unfavorable:

• Delayed presentation (fulminant phase)
• Inhalational or GI form
• Meningitis
• High bacterial load (> 10⁶ CFU/mL on blood culture)
• Shock requiring vasopressors
• Multi-organ failure
• DIC
• Older age, immunocompromised

Long-Term Outcomes

Survivors of systemic anthrax:

• Neurological sequelae: Cognitive impairment, seizures, focal deficits (if meningitis)
• Pulmonary fibrosis: Chronic respiratory impairment (post-ARDS)
• Chronic fatigue: Post-critical illness syndrome
• Psychological: PTSD (especially bioterrorism survivors)

Survivors of cutaneous anthrax:

• Scarring at eschar site
• Usually no long-term sequelae

Reinfection: Possible (naturally acquired immunity is incomplete); vaccination provides more reliable protection

---

10. Prevention

Primary Prevention

Human Vaccination

Anthrax Vaccine Adsorbed (AVA):

• Target groups: Military personnel deployed to high-risk areas, laboratory workers handling B. anthracis, certain animal product workers
• Not routinely recommended for general population
• Availability: Limited to national stockpiles

Decontamination

Environmental spore decontamination (bioterrorism event):

Personal decontamination (spore exposure):

• Remove clothing (place in biohazard bags)
• Shower with soap and water
• Start PEP (antimicrobials ± vaccine)

---

11. Evidence and Guidelines

Key Guidelines

Landmark Evidence

---

12. Examination Focus

High-Yield Topics for MRCP/Infectious Diseases Exams

Clinical Recognition

Classic Scenarios:

1. Cutaneous Anthrax:

   • "A farmer presents with a painless black lesion on his forearm surrounded by massive swelling after handling a dead sheep."
   • Key: Painless eschar + oedema + animal contact

2. Inhalational Anthrax:

   • "A postal worker develops flu-like illness followed by sudden respiratory distress. CXR shows widened mediastinum."
   • Key: Biphasic illness + widened mediastinum + occupational context

3. Bioterrorism:

   • "Multiple patients present to EDs with flu-like illness followed by respiratory failure after white powder incident."
   • Key: Multiple simultaneous cases + suspicious exposure

Viva Questions and Model Answers

Q1: Describe the appearance of cutaneous anthrax.

Model Answer: "Cutaneous anthrax presents as a characteristic painless black eschar, typically 1-3 cm in diameter, surrounded by massive gelatinous, non-pitting oedema that extends far beyond the lesion. The term 'anthrax' derives from the Greek word for coal, referring to the coal-black appearance. The lesion evolves over 7-10 days from an initial pruritic papule → vesicle → ulcer → eschar. The painlessness is a key distinguishing feature; pain suggests secondary bacterial infection or an alternative diagnosis."

Q2: What is the pathognomonic chest radiograph finding in inhalational anthrax, and what causes it?

Model Answer: "The pathognomonic finding is widened mediastinum, defined as > 8 cm at the level of T4 vertebra. This results from haemorrhagic necrosis and massive enlargement of mediastinal lymph nodes due to bacterial replication and toxin production. Importantly, parenchymal infiltrates are typically absent in early disease, distinguishing it from community-acquired pneumonia. Haemorrhagic pleural effusions are commonly present. CT shows hyperdense (haemorrhagic) mediastinal lymph nodes."

Q3: What antimicrobial regimen would you use for inhalational anthrax with suspected meningitis?

Model Answer: "I would use IV triple combination therapy:

1. Ciprofloxacin 400 mg IV every 8 hours – bactericidal fluoroquinolone with activity against B. anthracis
2. Linezolid 600 mg IV every 12 hours – protein synthesis inhibitor that achieves excellent CSF penetration (> 80%) and inhibits further toxin production
3. Meropenem 2 g IV every 8 hours – provides additional Gram-positive coverage and good CSF penetration

I would also administer antitoxin (raxibacumab 40 mg/kg IV or anthrax immune globulin) to neutralize circulating toxin. Treatment duration is 60 days total (IV until stable, then complete with oral ciprofloxacin or doxycycline) to account for the prolonged germination period of spores."

Q4: Why is the treatment duration for anthrax 60 days?

Model Answer: "The 60-day duration is necessary because antimicrobials only kill vegetative (replicating) bacteria, not metabolically dormant spores. Spores can remain in tissues, particularly mediastinal lymph nodes, and germinate asynchronously over weeks. The Sverdlovsk outbreak documented cases emerging up to 43 days after exposure. Primate studies demonstrated that shorter courses resulted in disease relapse after spore germination. Therefore, 60 days of treatment is required to cover the maximal documented incubation/germination period and prevent relapse."

Q5: What are the components of anthrax toxin, and how do they cause disease?

Model Answer: "Anthrax toxin is a tripartite AB toxin system consisting of:

1. Protective Antigen (PA) – the B (binding) component that binds to cell surface receptors (ANTXR1/ANTXR2), is cleaved by furin protease, oligomerizes into a heptameric pore, and translocates the A (active) components into cells.

2. Lethal Factor (LF) – a zinc metalloprotease that cleaves MAPKKs, disrupting cellular signaling. This causes macrophage pyroptosis, cytokine storm, endothelial dysfunction, vascular leak, and shock.

3. Oedema Factor (EF) – a calmodulin-dependent adenylate cyclase that massively elevates intracellular cAMP, causing water dysregulation, impaired neutrophil function, and the characteristic gelatinous oedema.

PA combines with LF to form Lethal Toxin (LeTx), which causes systemic toxicity and death. PA combines with EF to form Oedema Toxin (EdTx), which causes massive local oedema. This binary toxin mechanism is the target of antitoxin therapy (raxibacumab, obiltoxaximab), which binds PA and prevents toxin assembly."

Q6: What are the indications for antitoxin therapy in anthrax?

Model Answer: "Antitoxin therapy (raxibacumab, obiltoxaximab, or anthrax immune globulin) is indicated for systemic anthrax, including:

• Inhalational anthrax
• Gastrointestinal anthrax
• Injectional anthrax
• Complicated cutaneous anthrax with systemic signs
• Anthrax meningitis

The rationale is that antibiotics kill bacteria but do not neutralize circulating toxin. Antitoxin binds protective antigen (PA), preventing toxin assembly and cellular entry. It is most effective when administered early, before extensive toxin-mediated tissue damage. It should be given after antimicrobials are started to avoid anaphylaxis from mass bacterial lysis."

Q7: Why is anthrax classified as a Category A bioterrorism agent?

Model Answer: "Bacillus anthracis is a Category A agent (highest threat level) because:

1. Environmental stability: Spores survive for decades in soil and resist heat, desiccation, and many chemical disinfectants.

2. Ease of dissemination: Spores can be produced in large quantities and aerosolized for wide distribution (low-tech weaponization).

3. High mortality: Inhalational anthrax has 45-90% mortality even with treatment.

4. Public panic potential: Historical use in warfare/bioterrorism (2001 postal attacks) creates fear.

5. Low infectious dose: ~8,000-50,000 spores can cause inhalational anthrax.

The 2001 US postal attacks demonstrated this threat, resulting in 22 cases and 5 deaths from letters containing spore powder. Extensive decontamination efforts were required for affected buildings."

Common Exam Mistakes to Avoid

❌ Mistake: Recommending airborne precautions for anthrax patients ✅ Correct: Standard precautions sufficient; anthrax is NOT contagious person-to-person

❌ Mistake: Treating cutaneous anthrax with 7-14 days of antibiotics ✅ Correct: 60-day course required (even for uncomplicated cutaneous disease)

❌ Mistake: Using monotherapy for inhalational anthrax ✅ Correct: Combination therapy (ciprofloxacin + linezolid + meropenem) + antitoxin

❌ Mistake: Expecting parenchymal infiltrates on CXR in inhalational anthrax ✅ Correct: Widened mediastinum with NO early infiltrates (distinguishes from pneumonia)

❌ Mistake: Describing cutaneous anthrax eschar as painful ✅ Correct: Painless (pain indicates secondary infection or wrong diagnosis)

❌ Mistake: Assuming anthrax is contagious and isolating contacts ✅ Correct: No person-to-person transmission; PEP only if shared common source exposure

---

13. Patient and Layperson Explanation

What is Anthrax?

Anthrax is a serious bacterial infection caused by a germ called Bacillus anthracis. This bacterium lives in soil as tough, resistant spores that can survive for many years. Anthrax mainly affects farm animals like cattle, sheep, and goats, but humans can get it from contact with infected animals or animal products.

How Do People Get Anthrax?

There are four ways to get anthrax:

1. Through the skin (most common): Spores enter through a cut, scrape, or insect bite when handling infected animals, wool, hides, or bone meal. This causes a painless black sore.

2. Breathing in spores (very serious): Inhaling spores can occur in certain jobs (processing wool or animal hides) or in a bioterrorism attack. This affects the lungs and is life-threatening.

3. Eating contaminated meat (rare): Occurs in areas where animal disease is common and meat is undercooked.

4. Injection (very rare): Reported in people who inject drugs, from contaminated heroin.

Is Anthrax Contagious?

No. Anthrax does NOT spread from person to person. You cannot catch it from someone who has anthrax. It only comes from direct exposure to the spores.

What Does Anthrax Look Like?

Skin anthrax causes a distinctive painless black scab (like a piece of coal) surrounded by swelling. The key features are:

• Black sore: Starts as a small bump, becomes a blister, then turns into a dry black scab
• Painless: Unlike most infections, it doesn't hurt
• Swelling: Massive swelling around the sore, much larger than the sore itself

If you develop this after contact with animals or animal products, see a doctor immediately.

Lung anthrax starts like the flu (fever, cough, tiredness) but then suddenly gets much worse with difficulty breathing. This is a medical emergency.

How is Anthrax Treated?

Anthrax is treated with antibiotics (usually ciprofloxacin or doxycycline). Treatment must be:

• Started early: The sooner treatment starts, the better the outcome
• Continued for 60 days: This long course is necessary because the bacterial spores can "wake up" weeks after initial exposure
• Taken exactly as prescribed: Don't stop early even if you feel better

For severe lung anthrax, treatment also includes:

• Hospital intensive care
• Intravenous antibiotics
• Special antitoxin medications
• Breathing support

What is the Outlook?

Skin anthrax: Almost always curable with antibiotics (> 99% survival)

Lung anthrax: Very serious even with treatment (about 50-60% survival with modern intensive care; much worse without treatment)

The key is early recognition and immediate treatment.

Can Anthrax Be Prevented?

For people at risk (farmers, veterinarians, certain workers):

• Use protective equipment when handling animals
• Vaccinate livestock in areas where anthrax is common
• Report sick or dead animals to veterinary authorities
• A vaccine exists for people at very high risk (military, laboratory workers)

After a bioterrorism exposure:

• People exposed to spores receive 60 days of antibiotics to prevent disease
• Vaccine may also be given

Anthrax and Bioterrorism

Anthrax has been used as a biological weapon. In 2001, letters containing anthrax spores were mailed in the United States, causing 22 infections and 5 deaths. This is why anthrax is taken very seriously by public health authorities.

If there is a suspected bioterrorism incident:

• Follow public health instructions
• Seek medical attention if you may have been exposed
• Preventive antibiotics will be provided to exposed individuals

Key Takeaways

✅ Anthrax comes from animals or animal products, NOT from other people

✅ Skin anthrax causes a painless black sore with swelling – very treatable

✅ Lung anthrax is a medical emergency – seek immediate care

✅ Treatment requires 60 days of antibiotics

✅ Early treatment is critical for the best outcome

---

14. References

Primary Sources

1. Hendricks KA, Wright ME, Shadomy SV, et al. Centers for Disease Control and Prevention expert panel meetings on prevention and treatment of anthrax in adults. Emerg Infect Dis. 2014;20(2):e130687. doi:10.3201/eid2002.130687. PMID: 24447897.

2. Sweeney DA, Hicks CW, Cui X, et al. Anthrax infection. Am J Respir Crit Care Med. 2011;184(12):1333-1341. doi:10.1164/rccm.201102-0209CI. PMID: 21852539.

3. Jernigan JA, Stephens DS, Ashford DA, et al. Bioterrorism-related inhalational anthrax: the first 10 cases reported in the United States. Emerg Infect Dis. 2001;7(6):933-944. doi:10.3201/eid0706.010604. PMID: 11747719.

4. Inglesby TV, O'Toole T, Henderson DA, et al. Anthrax as a biological weapon, 2002: updated recommendations for management. JAMA. 2002;287(17):2236-2252. doi:10.1001/jama.287.17.2236. PMID: 11980524.

5. Young JA, Collier RJ. Anthrax toxin: receptor binding, internalization, pore formation, and translocation. Annu Rev Biochem. 2007;76:243-265. doi:10.1146/annurev.biochem.75.103004.142728. PMID: 17335404.

6. Liu S, Moayeri M, Leppla SH. Anthrax lethal and edema toxins in anthrax pathogenesis. Trends Microbiol. 2014;22(6):317-325. doi:10.1016/j.tim.2014.02.012. PMID: 24684968.

7. Bower WA, Hendricks K, Pillai S, et al. Clinical framework and medical countermeasure use during an anthrax mass-casualty incident. MMWR Recomm Rep. 2015;64(RR-04):1-22. PMID: 26606127.

8. Meaney-Delman D, Rasmussen SA, Beigi RH, et al. Prophylaxis and treatment of anthrax in pregnant women. Obstet Gynecol. 2013;122(4):885-900. doi:10.1097/AOG.0b013e3182a5d05b. PMID: 24084549.

9. World Health Organization. Anthrax in Humans and Animals. 4th ed. Geneva: WHO Press; 2008. ISBN: 978-92-4-154753-6.

10. Goel AK. Anthrax: A disease of biowarfare and public health importance. World J Clin Cases. 2015;3(1):20-33. doi:10.12998/wjcc.v3.i1.20. PMID: 25610847.

11. Meselson M, Guillemin J, Hugh-Jones M, et al. The Sverdlovsk anthrax outbreak of 1979. Science. 1994;266(5188):1202-1208. doi:10.1126/science.7973702. PMID: 7973702.

12. Holty JE, Bravata DM, Liu H, et al. Systematic review: a century of inhalational anthrax cases from 1900 to 2005. Ann Intern Med. 2006;144(4):270-280. doi:10.7326/0003-4819-144-4-200602210-00009. PMID: 16490913.

13. Ramsay CN, Stirling A, Smith J, et al. An outbreak of infection with Bacillus anthracis in injecting drug users in Scotland. Euro Surveill. 2010;15(2):19465. PMID: 20085691.

14. Doganay M, Metan G, Alp E. A review of cutaneous anthrax and its outcome. J Infect Public Health. 2010;3(3):98-105. doi:10.1016/j.jiph.2010.07.004. PMID: 20869669.

15. Hicks CW, Sweeney DA, Cui X, et al. An overview of anthrax infection including the recently identified form of disease in injection drug users. Intensive Care Med. 2012;38(7):1092-1104. doi:10.1007/s00134-012-2541-0. PMID: 22527064.

16. Subramanian GM, Cronin PW, Poley G, et al. A phase 1 study of PAmAb, a fully human monoclonal antibody against Bacillus anthracis protective antigen, in healthy volunteers. Clin Infect Dis. 2005;41(1):12-20. doi:10.1086/430708. PMID: 15937757.

17. Migone TS, Subramanian GM, Zhong J, et al. Raxibacumab for the treatment of inhalational anthrax. N Engl J Med. 2009;361(2):135-144. doi:10.1056/NEJMoa0810603. PMID: 19587338.

18. Walsh JJ, Pesik N, Quinn CP, et al. A case of naturally acquired inhalation anthrax: clinical care and analyses of anti-protective antigen immunoglobulin G and lethal factor. Clin Infect Dis. 2007;44(7):968-971. doi:10.1086/512372. PMID: 17342653.

---

Medical Disclaimer: MedVellum content is for educational purposes and clinical reference. Clinical decisions should account for individual patient circumstances. Always consult appropriate specialists and follow local guidelines. In suspected bioterrorism events, immediately notify public health authorities and law enforcement.